Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Total Liabilities (2018 - 2025)

Cyclerion Therapeutics has reported Total Liabilities over the past 8 years, most recently at $900000.0 for Q4 2025.

  • For Q4 2025, Total Liabilities rose 24.14% year-over-year to $900000.0; the TTM value through Dec 2025 reached $900000.0, up 24.14%, while the annual FY2025 figure was $900000.0, 24.14% up from the prior year.
  • Total Liabilities for Q4 2025 was $900000.0 at Cyclerion Therapeutics, up from $877000.0 in the prior quarter.
  • Over five years, Total Liabilities peaked at $51.5 million in Q1 2021 and troughed at $700000.0 in Q3 2024.
  • A 5-year average of $7.2 million and a median of $3.6 million in 2023 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: tumbled 83.03% in 2021 and later grew 25.29% in 2025.
  • Year by year, Total Liabilities stood at $11.1 million in 2021, then plummeted by 31.2% to $7.6 million in 2022, then tumbled by 72.65% to $2.1 million in 2023, then plummeted by 65.24% to $725000.0 in 2024, then grew by 24.14% to $900000.0 in 2025.
  • Business Quant data shows Total Liabilities for CYCN at $900000.0 in Q4 2025, $877000.0 in Q3 2025, and $800000.0 in Q2 2025.